1Lusuardi M,Cape 1 li A,Carli S,etal.Role of surfactant in chronic obst ructive pulmonary disease:therapeuticimplications.Respiration,1992,59(Suppl 1): 28-32.
2Gillissen A,Nowak D.Characterization of N-acetylcysteine and ambroxol inanti-oxedant therapy.Respir Med,1998,92(4):609-623.
3Houtmeyers E.Effects of drugs on mucus clearance.Eur Respir J,1999,1 4(2):452-467.
4Zasshi NY.Effects of ambroxol HC1 on the guinea pig tracheal mucous secretion andthe rat pulmonary surfactant secretion.Uchida-M,1992,100(4):293-30 0.
5Derelle J,Bertolo HE,Marchal F,et al.Respiratory evolution of patien t withmucoviscidosis treated with mucolytic agents plus dornase alfa.Arch-Pediatr,1998,5(4):371-377.
6Nowak D,Antczak A,Krol M,et al.Antioxidant properties of ambroxol.Fr ee Radic BiolMed,1994,16(4):517-522.
8Dorow P,Weiss T.Modification of mucociliary clearance by a combinati on oftheophylline with ambroxol and of ambroxol in monotherapy.Arzneimittelforschung,1988,38(6):828-830.
10Michnar M,Milanowski J.Clinical evaluation of efficacy and tolerance oforaltreatment with ambroxol in patients with chronic bronchitis.Pneumonol-Alergol-Pol,1996,64(Suppl 1):90-96.
7HAYES B D, DONOVAN J L, SMITH B S, et al. Pharmacist--conducted medication reconciliation in an emergency department [J]. Am J Health Syst Pharm, 2007, 64(16): 1720-1723.
8The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for potentially inappropriate medication use in older adults [J]. J Am Geriatr Soc, 2012, 60(4): 616-631.
9O'MAHONY D, GALLAGHER P, RYAN C, et al. STOPP&START criteria: A new approach to detecting potentially inappropriate prescribing in old age [J]. Eur Ger Med, 2010, 1(1): 45-51.
10SONG Y T. Interdisciplinary integrated management for aged diseases[J].中国现代医师,2012,50(22):118-120.
